Tokyo Tape
Sign in
← Otsuka Holdings

Quarterly report · Q1

4578.TEDINET S100TCFM
Period2024-01-01 → 2024-03-31
Filed2024-04-30
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
MetricValuePeriodScopeSource row
Revenue¥519.5bn2024-01-01 → 2024-03-31Cons.Revenue IFRS
Revenue¥2.02T2023-01-01 → 2023-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥448.3bn2023-01-01 → 2023-03-31Cons.Revenue IFRS
Operating income¥92.0bn2024-01-01 → 2024-03-31Cons.Operating profit loss IFRS
Operating income¥76.8bn2023-01-01 → 2023-03-31Cons.Operating profit loss IFRS
Profit before tax¥100.1bn2024-01-01 → 2024-03-31Cons.Profit loss before tax IFRS
Profit before tax¥142.7bn2023-01-01 → 2023-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥79.2bn2023-01-01 → 2023-03-31Cons.Profit loss before tax IFRS
Net income (owners)¥77.4bn2024-01-01 → 2024-03-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥121.6bn2023-01-01 → 2023-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥61.4bn2023-01-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS
Net income¥78.9bn2024-01-01 → 2024-03-31Cons.Profit loss IFRS
Net income¥62.7bn2023-01-01 → 2023-03-31Cons.Profit loss IFRS
Total assets¥3.45Tat 2024-03-31Cons.Assets IFRS
Total assets¥3.36Tat 2023-12-31Cons.Assets IFRS
Total assets¥3.13Tat 2023-03-31Cons.Total assets IFRS (5-year summary)
Total liabilities¥894.5bnat 2024-03-31Cons.Liabilities IFRS
Total liabilities¥924.9bnat 2023-12-31Cons.Liabilities IFRS
Net assets / equity¥2.56Tat 2024-03-31Cons.Equity IFRS
Net assets / equity¥2.44Tat 2023-12-31Cons.Equity IFRS
Net assets / equity¥2.32Tat 2023-03-31Cons.Equity IFRS
Net assets / equity¥2.26Tat 2022-12-31dCons.Equity IFRS
Equity (owners)¥2.51Tat 2024-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥2.39Tat 2023-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥2.28Tat 2023-03-31Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥411.6bnat 2024-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥513.3bnat 2023-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥477.1bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥471.6bnat 2022-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥36.4bn2024-01-01 → 2024-03-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥283.2bn2023-01-01 → 2023-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥71.9bn2023-01-01 → 2023-03-31Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥91.5bn2024-01-01 → 2024-03-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥190.5bn2023-01-01 → 2023-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥35.8bn2023-01-01 → 2023-03-31Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥58.7bn2024-01-01 → 2024-03-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥60.3bn2023-01-01 → 2023-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥32.7bn2023-01-01 → 2023-03-31Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥142.592024-01-01 → 2024-03-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥224.12023-01-01 → 2023-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥113.22023-01-01 → 2023-03-31Cons.Basic earnings loss per share IFRS
EPS (diluted)¥142.592024-01-01 → 2024-03-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥224.12023-01-01 → 2023-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥113.182023-01-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS
Equity ratio72.8%at 2024-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio71.2%at 2023-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio72.8%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 44
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2024-01-01 → 2024-03-31¥27.3bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2024-01-01 → 2024-03-31¥26.4bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2024-01-01 → 2024-03-31¥872m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2024-01-01 → 2024-03-31¥1.9bn
Reconciling Itemsreconcilingrevenue2024-01-01 → 2024-03-31−¥881m
Reconciling Itemsreconcilingrevenue intersegment2024-01-01 → 2024-03-31−¥881m
Reconciling Itemsreconcilingsegment profit2024-01-01 → 2024-03-31−¥10.8bn
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentrevenue2024-01-01 → 2024-03-31¥7.3bn
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentrevenue external2024-01-01 → 2024-03-31¥7.3bn
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentrevenue intersegment2024-01-01 → 2024-03-31¥1m
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentsegment profit2024-01-01 → 2024-03-31¥4.3bn
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentrevenue2024-01-01 → 2024-03-31¥126.2bn
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentrevenue external2024-01-01 → 2024-03-31¥126.2bn
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentrevenue intersegment2024-01-01 → 2024-03-31¥6m
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentsegment profit2024-01-01 → 2024-03-31¥16.8bn
jpcrp040300-q1r_E21183-000Pharmaceuticalsreportable segmentrevenue2024-01-01 → 2024-03-31¥359.6bn
jpcrp040300-q1r_E21183-000Pharmaceuticalsreportable segmentrevenue external2024-01-01 → 2024-03-31¥359.6bn
jpcrp040300-q1r_E21183-000Pharmaceuticalsreportable segmentsegment profit2024-01-01 → 2024-03-31¥79.8bn
—segment totalrevenue2024-01-01 → 2024-03-31¥520.4bn
—segment totalrevenue external2024-01-01 → 2024-03-31¥519.5bn
—segment totalrevenue intersegment2024-01-01 → 2024-03-31¥881m
—segment totalsegment profit2024-01-01 → 2024-03-31¥102.8bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-01-01 → 2023-03-31¥27.3bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-01-01 → 2023-03-31¥26.6bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-01-01 → 2023-03-31¥723m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-01-01 → 2023-03-31¥3.1bn
Reconciling Itemsreconcilingrevenue2023-01-01 → 2023-03-31−¥742m
Reconciling Itemsreconcilingrevenue intersegment2023-01-01 → 2023-03-31−¥742m
Reconciling Itemsreconcilingsegment profit2023-01-01 → 2023-03-31−¥12.9bn
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentrevenue2023-01-01 → 2023-03-31¥8.2bn
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentrevenue external2023-01-01 → 2023-03-31¥8.2bn
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentrevenue intersegment2023-01-01 → 2023-03-31¥4m
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentsegment profit2023-01-01 → 2023-03-31¥2.2bn
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentrevenue2023-01-01 → 2023-03-31¥104.0bn
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentrevenue external2023-01-01 → 2023-03-31¥104.0bn
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentrevenue intersegment2023-01-01 → 2023-03-31¥13m
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentsegment profit2023-01-01 → 2023-03-31¥10.8bn
jpcrp040300-q1r_E21183-000Pharmaceuticalsreportable segmentrevenue2023-01-01 → 2023-03-31¥309.5bn
jpcrp040300-q1r_E21183-000Pharmaceuticalsreportable segmentrevenue external2023-01-01 → 2023-03-31¥309.5bn
jpcrp040300-q1r_E21183-000Pharmaceuticalsreportable segmentsegment profit2023-01-01 → 2023-03-31¥73.6bn
—segment totalrevenue2023-01-01 → 2023-03-31¥449.1bn
—segment totalrevenue external2023-01-01 → 2023-03-31¥448.3bn
—segment totalrevenue intersegment2023-01-01 → 2023-03-31¥742m
—segment totalsegment profit2023-01-01 → 2023-03-31¥89.7bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 694
ItemContextValueUnit
Trade and other payables2 cl IFRSCurrentQuarterInstant193428000000JPY
Bonds and borrowings cl IFRSPrior1YearInstant69425000000JPY
Bonds and borrowings cl IFRSCurrentQuarterInstant52677000000JPY
Lease liabilities cl IFRSPrior1YearInstant18847000000JPY
Lease liabilities cl IFRSCurrentQuarterInstant19298000000JPY
Other financial liabilities cl IFRSPrior1YearInstant－JPY
Other financial liabilities cl IFRSCurrentQuarterInstant1356000000JPY
Income taxes payable cl IFRSPrior1YearInstant54939000000JPY
Income taxes payable cl IFRSCurrentQuarterInstant46101000000JPY
Provisions cl IFRSPrior1YearInstant919000000JPY
Provisions cl IFRSCurrentQuarterInstant1060000000JPY
Contract liabilities cl IFRSPrior1YearInstant14322000000JPY
Contract liabilities cl IFRSCurrentQuarterInstant13237000000JPY
Other current liabilities cl IFRSPrior1YearInstant302410000000JPY
Other current liabilities cl IFRSCurrentQuarterInstant304308000000JPY
Total current liabilities IFRSPrior1YearInstant667233000000JPY
Total current liabilities IFRSCurrentQuarterInstant631469000000JPY
Bonds and borrowings ncl IFRSPrior1YearInstant69200000000JPY
Bonds and borrowings ncl IFRSCurrentQuarterInstant68673000000JPY
Lease liabilities ncl IFRSPrior1YearInstant56715000000JPY
Lease liabilities ncl IFRSCurrentQuarterInstant58818000000JPY
Other financial liabilities ncl IFRSPrior1YearInstant16774000000JPY
Other financial liabilities ncl IFRSCurrentQuarterInstant18493000000JPY
Retirement benefit liability ncl IFRSPrior1YearInstant16557000000JPY
Retirement benefit liability ncl IFRSCurrentQuarterInstant15103000000JPY
Provisions ncl IFRSPrior1YearInstant2252000000JPY
Provisions ncl IFRSCurrentQuarterInstant2338000000JPY
Contract liabilities ncl IFRSPrior1YearInstant44869000000JPY
Contract liabilities ncl IFRSCurrentQuarterInstant42674000000JPY
Deferred tax liabilities IFRSPrior1YearInstant27170000000JPY
Deferred tax liabilities IFRSCurrentQuarterInstant28088000000JPY
Other non current liabilities ncl IFRSPrior1YearInstant24152000000JPY
Other non current liabilities ncl IFRSCurrentQuarterInstant28872000000JPY
Non current labilities IFRSPrior1YearInstant257692000000JPY
Non current labilities IFRSCurrentQuarterInstant263062000000JPY
Liabilities IFRSPrior1YearInstant924926000000JPY
Liabilities IFRSCurrentQuarterInstant894532000000JPY
Share capital IFRSPrior1YearInstant81690000000JPY
Share capital IFRSCurrentQuarterInstant81690000000JPY
Capital surplus IFRSPrior1YearInstant506230000000JPY
Capital surplus IFRSCurrentQuarterInstant506224000000JPY
Treasury shares IFRSPrior1YearInstant-44669000000JPY
Treasury shares IFRSCurrentQuarterInstant-44669000000JPY
Retained earnings IFRSPrior1YearInstant1621218000000JPY
Retained earnings IFRSCurrentQuarterInstant1666697000000JPY
Other components of equity IFRSPrior1YearInstant229214000000JPY
Other components of equity IFRSCurrentQuarterInstant301643000000JPY
Equity attributable to owners of parent IFRSPrior1YearInstant2393683000000JPY
Equity attributable to owners of parent IFRSCurrentQuarterInstant2511586000000JPY
Non controlling interests IFRSPrior1YearInstant42634000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-12-31pass rounding
balance sheet identityconsolidated 2024-03-31pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-03-31pass
statement vs summary · net income attributable to parentconsolidated 2024-01-01/2024-03-31pass
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-03-31pass
statement vs summary · operating cash flowconsolidated 2024-01-01/2024-03-31pass
statement vs summary · revenueconsolidated 2023-01-01/2023-03-31pass
statement vs summary · revenueconsolidated 2024-01-01/2024-03-31pass
statement vs summary · total assetsconsolidated 2023-12-31pass
statement vs summary · total assetsconsolidated 2024-03-31pass